Treatment of malignant pleural effusions with intrapleural Corynebacterium parvum or tetracycline.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108011
Title:
Treatment of malignant pleural effusions with intrapleural Corynebacterium parvum or tetracycline.
Authors:
Leahy, B; Honeybourne, D; Brear, S G; Carroll, K B; Thatcher, Nick; Stretton, T B
Abstract:
Thirty two patients with malignant pleural effusion were randomly allocated to treatment with intrapleural Corynebacterium parvum or tetracycline hydrochloride in an attempt to prevent symptomatic recurrence of pleural fluid. Success in preventing recurrence of fluid at one month, using up to 2 doses of each drug, was 14 of 16 cases for Corynebacterium parvum, 5 of 9 for tetracycline given via an intercostal needle, and 6 of 7 for tetracycline given through an intercostal tube. These difference were not statistically significant. Corynebacterium parvum was significantly more likely to produce pyrexia equal or greater than 38 degrees C (P less than 0.001) and pain requiring analgesia (P less than 0.05) than tetracycline hydrochloride. Corynebacterium parvum is a useful agent for the management of malignant pleural effusion, but is associated with more side effects than tetracycline.
Citation:
Treatment of malignant pleural effusions with intrapleural Corynebacterium parvum or tetracycline. 1985, 66 (1):50-4 Eur J Respir Dis
Journal:
European Journal of Respiratory Diseases
Issue Date:
Jan-1985
URI:
http://hdl.handle.net/10541/108011
PubMed ID:
3979476
Type:
Article
Language:
en
ISSN:
0106-4339
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorLeahy, Ben
dc.contributor.authorHoneybourne, Den
dc.contributor.authorBrear, S Gen
dc.contributor.authorCarroll, K Ben
dc.contributor.authorThatcher, Nicken
dc.contributor.authorStretton, T Ben
dc.date.accessioned2010-07-21T10:34:59Z-
dc.date.available2010-07-21T10:34:59Z-
dc.date.issued1985-01-
dc.identifier.citationTreatment of malignant pleural effusions with intrapleural Corynebacterium parvum or tetracycline. 1985, 66 (1):50-4 Eur J Respir Disen
dc.identifier.issn0106-4339-
dc.identifier.pmid3979476-
dc.identifier.urihttp://hdl.handle.net/10541/108011-
dc.description.abstractThirty two patients with malignant pleural effusion were randomly allocated to treatment with intrapleural Corynebacterium parvum or tetracycline hydrochloride in an attempt to prevent symptomatic recurrence of pleural fluid. Success in preventing recurrence of fluid at one month, using up to 2 doses of each drug, was 14 of 16 cases for Corynebacterium parvum, 5 of 9 for tetracycline given via an intercostal needle, and 6 of 7 for tetracycline given through an intercostal tube. These difference were not statistically significant. Corynebacterium parvum was significantly more likely to produce pyrexia equal or greater than 38 degrees C (P less than 0.001) and pain requiring analgesia (P less than 0.05) than tetracycline hydrochloride. Corynebacterium parvum is a useful agent for the management of malignant pleural effusion, but is associated with more side effects than tetracycline.en
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshBacterial Vaccines-
dc.subject.meshDrug Evaluation-
dc.subject.meshFemale-
dc.subject.meshFever-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasms-
dc.subject.meshPain-
dc.subject.meshPleural Effusion-
dc.subject.meshPropionibacterium acnes-
dc.subject.meshRandom Allocation-
dc.subject.meshTetracyclines-
dc.titleTreatment of malignant pleural effusions with intrapleural Corynebacterium parvum or tetracycline.en
dc.typeArticleen
dc.identifier.journalEuropean Journal of Respiratory Diseasesen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.